You are here

IdentifySensors Biologics


Make an investment in IdentifySensors Biologics.


PURDUE PARTNERS WITH IDENTIFYSENSORS · Purdue University has partnered with IdentifySensors Biologics to develop all new nanosensors that instantly detect COVID-19 RNA in saliva. This breakthrough is intended to significantly reduce delays and errors associated with other instant home tests, which miss more than 50 percent of early and asymptomatic infections.

This over-the-counter self-test, which is intended to be performed entirely at home on a smartphone, is in final stages of development at Purdue University. The test is intended to meet the gold-standard of PCR testing, but without delayed results from a doctor's visit, prescirptions or lab work. The partnership includes some of the world’s most prestigious experts in molecular biology, diagnostics, materials engineering.


Purdue University and IdentifySensors Biologics have partnered to create Check4-COVID™: a highly accurate, over-the-counter home test intended to immediately detect COVID-19 RNA in early and asymptomatic infections. The test uses newly developed nanosensors, saliva and a smartphone to instantly pinpoint infections that current home tests miss more than 50 percent of the time.

The reusable test reader is intended to cost $130. Each COVID test cartridge is intended to cost less than $25. Both are intended to be released to the public with FDA approval this year. This patented and patent-pending technology can be easily modified to detect influenza, HIV/AIDS, lyme disease, and other ailments—offering investors long-term value past the pandemic. 


Early and asymptomatic infections play the single largest role in the spread of the pandemic. CDC reseaerch shows that long waits and false results are allowing the virus to speead at record speeds. Check4-COVID™ is intended to be the solution. It is intended to be an instant, affordable self-test for smartphones that catches spreadable infections other tests miss. It is intended to be used entirely at home without a lab or a prescription. This test, along with new vaccines, is intended to be the tipping point that finally curbs the pandemic. 

Ready to invest?

Help get this test to market and support the COVID self-test that detects infections most home tests miss.


New CDC research found that people who don't show COVID symptoms may be responsible for 59 percent of transmissions, comprising 35 percent who are presymptomatic and 24 percent who never develop symptoms at all. Check4-COVID is intended to catch these infections instantly and at home to fill a significant gap in manging the pandemic.



Antigen test results are wrong most of the time. PCR tests require a doctor, a lab and long wait times for results. A highly accurate, affordable home test that instantly catches early and asymptomatic infections is the breakthrough that will finally slow the pandemic. There is currently no home test that is both accurate enough and fast enough to sow the spread. Check4-COVID™ uses all-new technology intended to not only slow viral transmission; it is intended to set new standards in home diagnostics for a wide variety of pathogens. It is intended that consumers will soon have a testing laboratory in their medicine cabinet, forever changing the face of clinical diagnostics.




Ready to invest?

Help get this test to market soon, curb the pandemic and help everyone get back to normal.


Check4-COVID™ is inteneded to meet an immediate public need, but our technology has the capability to go beyond COVID-19 testing to provide rapid results among a wide range of pathogens. Our focus for the near future include:


Most home tests produce a high percentage of false positives and false negatives. With the help of infectious disease specialists at Purdue University, we’ve designed Check4-COVID™ to meet the gold-standard in hospital-grade molecular testing that is taken entirely at home without a prescription and long wait times.

Why Do Current COVID Tests Give False Results?

The accuracy of current tests depends on:

A good sample or nasal swab that is well preserved and transported to a lab without contamination. Current home tests rely on untrained users.

Amplification of the virus. Current chemical tests can’t detect COVID-19 without amplification. In many cases, samples have insufficient virus material, requiring the test to multiply the virus millions of times.

Preparing the sample. Once a sample safely reaches a laboratory, it is chemically treated. If the wrong reagents are used, or if they have deteriorated, this offers yet another opportunity for error.

What Makes Check4-COVID™ Different from Current Tests?

Check4-COVID™ accurately detects COVID-19 through newly developed nanosensors, without the need for a lab, amplification or chemical reactions. This means:

No need to transport a clean sample to a lab and risk contamination.

No amplification of the virus is needed.

No need to prepare the sample in a lab for machine testing.

Ready to invest?

Help get this test to market soon and support the fast, accurate, and affordable smartphone-connected COVID self-test.


Our team includes world-leading scientists, executives and business advisors, who ensure our ability to deliver this test to market soon. We have the expertise and credentials to bring Check4-COVID™ to consumers, hospitals and point-of-care facilties worldwide.


Gregory Hummer

Co-Founder & CEO

Bruce Raben


Tommy Sors


Ann Hawkins


Jeff Spagnola



Lia Stanciu


Amit Barui

Research Associate

Rupesh Mishra

Research Scientist

Rodney Corder



Richard Kuhn


Dick Buell


Stephan Barrett



The director of Purdue University's Institute of Inflammation Immunology and Infectious Diseases, who worked with the recent Nobel Prize-winning team.

The assistant director of Purdue's Institute of Inflammation, Immunology and Infectious Diseases, whose renowned work focused on molecular biology.

One of the world's leading researchers in materials engineering at Purdue University.

A leading biomedical researcher at Purdue University.

A former Cleveland Clinic Surgeon and NASA Consultant.

A biomedical engineering professor at North Carolina State University, who has published more than 200 peer-reviewed articles in biomedical materials.

A former CMO of Cisco Systems.

A founding partner of Hudson Capital Advisors.

A former electrical engineering manager for Rockwell Automation.

A former CFO of Whirlpool and Procter & Gamble.

A former CEO of Catalina Marketing Corp., who serves on the boards of the American Society of Mechanical Engineers, SC Johnson, and Prestige Brands.


Your investment will help us to
manufacture, market, and distribute
Check4-COVID™ worldwide.

Ready to invest?

Help get this test to market soon and support the fast, accurate, and affordable smartphone-connected COVID self-test.

In the News

Check4-COVID™ FAQs

Product Questions

1. What does IdentifySensors Biologics do?
Check4-COVID™ is intended to be a fast, accurate and affordable saliva self-test for COVID-19. Results are displayed within minutes on a smartphone app, with accuracy that far exceeds current rapid home tests. 

2. How is Check4 COVID different from all other COVID tests?
New CDC research shows that current rapid home tests give false results more than 50 percent of the time. Check4-COVID is intended to be an entiely at-home instant test with accuracy above 90 percent. Reducing false negatives by this margin will be critical to curbing the pandemic and slowing the spread.   

3. Do healthcare professionals need to administer the test?
No. Check4-COVID™ is intended to be a simple self-test, similar to a home DNA test. Check4-COVID™ allows consumers to test their saliva on a device that connects to a smartphone. Results appear on the app within minutes in the privacy of a user’s home.

4. How does the test work?
Consumers buy a small, simple device online or from a retail store and download the free smartphone app. A saliva sample is placed in the device, and the results appear within minutes on the app. It is intended that inexpensive replaceable cartridges will allow endless, affordable testing on each device.

5. How accurate is Check4-COVID™?
Following FDA approval, Check4-COVID™ intends to meet the gold-standard in hospital-grade molecular COVID testing with minimal false positives. This is significantly better than curent home rapid tests. 

6. Why does the test notify health authorities?
By law, all COVID test results must be reported to health authorities to help manage the pandemic. Check4-COVID™ is an electronic-based, self-test that fulfills legal reporting requirements automatically through smartphones.

7. Why does the test use a smartphone app?
Chemical-based tests often rely on visual indicators. Check4-COVID™ uses an electronic circuit, which enables a signal to be sent to smartphones. The app then reports results to health authorities, which is required by law.

8. What if I don’t have a smartphone?
The smartphone app allows multiple users on a single device. This enables family members who do not have smartphones to use the device and app belonging to someone with a smartphone.

9. Do I have to buy multiple devices to test other family members?
No. A family can share the same device. The smartphone app is intended to allow multiple users so family members can share the same app and device, while interchanging different test cartridges.

10. Is the Smartphone app HIPAA compliant? What happens to my personal information?
By law, all test results must be reported to state and federal health authorities. All information collected by the IdentifySensors app is confidential and shared only with government agencies that require it. Some test results are de-identified, meaning that names are removed from the test results. All data is treated by the same high standards as secure hospital records. The app is securely encrypted and fully HIPAA compliant.

11. Can I turn off the reporting function of the app?
No. By law, all test results for contagious diseases must be reported to state, and federal health authorities. All information collected by the Check4-COVID™ app is encrypted, confidential, and follows high hospital standards for HIPAA-compliant privacy.

12. How much will the test cost?
It is intended that the reusable reader will cost $130. Each test cartridge will cost less than $25. The accuracy of the test and the low cost are intended to promore more frequent testing.

13. How can I be sure the test is accurate?
World-renowned scientists at Purdue University, who specialize in infectious diseases, have been developing and verifying the test’s accuracy for commercialization. The test is intended to be available to consumers following FDA approval, which is anticipated this year.

14. What is the problem with current rapid tests?
New CDC research shows that more than 50 percent of curent rapid test results are incorrect. Most PCR tests currently in use are expensive and take far too long for the results. These chemical-based tests often require samples to be transported to a laboratory for results.

15. When will the test be available to consumers?
Industry-leading scientists at Purdue University who specialize in infectious diseases have been developing and verifying the test for commercialization. The test is intended to be available to consumers following FDA approval this year.

16. Where will the test be sold?
Check4-COVID™ is intended to be sold online and through retail stores, such as pharmacies and grocery stores. High-volume commercial versions of the test are intended to be available to healthcare facilities and businesses through wholesale channels.

17. Can the test be used to minimize quarantine times?
Yes. Check4-COVID™ is intended to be fast, inexpensive and accurate, which enables frequent self-testing at home and without wait. Individuals infected with COVID-19, who quarantine at home, can self-test as often as they like to minimize quarantine times and return to their lives as soon as possible.

18. Is the test technology patented?
Yes, IdentifySensors holds several patents on various facets of the technology. Other patents are pending.

19. When will the product be available on the market?
Product development is in its final stages now. It is intended that the test will be available in 2021, following FDA approval.

20. How long will the FDA approval process take?
Check4-COVID™ soon will be submitted for FDA approval. We cannot be sure how long that process will last, but the process typically lasts a few weeks.

21. What plans does the company have for the product have after the pandemic?
The unique technology enables the test to be easily modified for other pathogens, including other coronaviruses, influenza, Zika, dengue, HIV/AIDS, hepatitis C, Lyme disease, mumps, measles, chickenpox, and methicillin-resistant staphylococcus Aureus (MRSA), as well as foodborne pathogens.

Pandemic Questions

22. How will this test help curb the pandemic?
The majority of COVID transmitions are spread by asymptomatic and early infections. PCR tests can take days for the results, and rapid home tests are incorrect more than 50 percent of the time. Check4-COVID is intended to provide immediate results with the accuracy of a PCR lab test. It is the best of both tests. Experts agree that vaccines and the combination of instant and accurate testing holds the key to curbing the pandemic.  

23. How can businesses benefit from this test?
Customers and employees could be allowed into facilities more readily with more frequent testing. Offices, manufacturing facilities, and restaurants, for example, could require self-tests of their employees. Sports facilities, airlines, and concert halls, for example, could require fans to display their self-test results on their smartphones before entering.

24. How will the test benefit hospitals, health care facilities, and nursing homes?
The self-tests are intended to be fast, accurate, and affordable. Frontline workers, and nursing-home employees, for example, could test themselves, and their patients daily, and isolate positive cases. Slowing the spread of the virus can help hospitals manage the best use of their facilities.

Investment Questions

25. Why did you use Regulation A+ and not venture capital or other types of funding?
Regulation A+ opens investment opportunities to anyone, regardless of their wealth or income. IdentifySensors biologics wanted to offer this opportunity to everyone interested in this exciting project. IdentifySensors Biologics is particularly well-suited for Regulation A+ because of the welcoming atmosphere the company provides.

26. What happens now that I’ve made an investment?
IdentifySensors Biologics will communicate news regularly. Our first messages will be about processing your investment payment and issuing your shares. Beyond that, we will notify you regularly about company milestones. As a Regulation A+ company, we are required to make annual and semi-annual filings with the SEC, all of which will be available on the SEC’s EDGAR filing system. The filings include:

  • Annual filings on Form 1-K, which are due each year and include audited financial statements for the previous fiscal year.
  • Semi-annual filings on Form 1-SA, which will include unaudited financial statements for the previous six months.
  • Form 1-U will announce important company events, such as leadership changes, a change in auditors, or certain types of capital-raising.


27. Can I invest if I am outside of the United States?
Yes. Investors around the world are welcome to invest. However, certain country restrictions might apply. Investors should consult their legal advisers about their ability to invest. Investors in Canada are prevented from investing in Regulation A+ by Canadian securities regulations.

28. How do I sell my shares?
These shares are not intended to list on a major exchange after the Regulation A+ offering. Because the shares are currently not listed on a stock exchange, there is no active market. However, these securities will not be restricted and can be freely traded to the extent any market develops for them from the date that an investor receives their shares. This is an advantage of Regulation A+ compared to other public offerings of private companies because securities regulations allow investors to sell their shares immediately. We intend to list our shares on a new Regulation A+ aftermarket listing services, which we intend to select after we complete this offering. We expect initially that there will be limited liquidity in this market. The company currently has no plans to seek listing or quotation of the securities on the NASDAQ, NYSE, or the OTC markets. In the future, the company may choose to list the company on a major public stock exchange to bring liquidity to the shares

29. Can I still invest if I am not an accredited investor?
Yes, investors of any wealth level over 18 years of age may participate in the Regulation A+ offering.

30. Do my shares have voting rights?
Yes, one vote per share.

31. Can I add shares to my initial investment?
Yes, but each new investment must be at least $300.

Ready to invest?

Help get this test to market soon and support the fast, accurate, and affordable smartphone-connected COVID self-test.


Post comment

IdentifySensors Biologics on January 11
We were recently asked if buyers can purchase IdentifySensors Biologics stock through a broker? Unfortunately, you cannot. Buyers can only purchase through this site. However, buyers can use money in their brokerage account, but a broker cannot make the purchase on someone else's behalf.

IdentifySensors Biologics on December 23
We were asked about liquidity: The company intends to list the Regulation A+ shares on one of the Regulation A+ aftermarkets when the offering has completed. This is called Alternative Trading System or ATS. We are in the process of evaluating aftermarket options that will work best for our investors. These aftermarkets allow Reg A+ investors to buy and sell their securities. Because these markets are relatively new, we do not yet know how much liquidity they will provide. In the future we may elect to list the company on a major exchange like the NASDAQ. There can be no assurance that such a listing will occur.

IdentifySensors Biologics on December 23
We were asked if these shares will pay dividends. At this time, we expect the company will invest any profits back into its business. However, if the operation of the company produces sufficient profits that the Board of Directors determines the company should make distributions of profits to shareholders, the company will make dividend distributions to it’s Reg A+ shareholders.

IdentifySensors Biologics on December 23
We received the question: "Will insurance cover the cost of this test?" Our response: Insurance companies may cover the test cost as some do currently.

IdentifySensors Biologics on December 23
We received a question asking if Manhattan Street Capital is the only investment house with this offering. The answer is yes.

IdentifySensors Biologics on December 23
Our investment team was asked: "How is Manhattan Street Capital being compensated?" The Answer: Manhattan Street Capital is a paid fixed consulting and listing fees. For each investment, the company is paid $25 in cash and warrants on our stock.

Offering Circular

Please read the Offering Circular here: Get Offering Circular